(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Building an Individual Brand: Illustrations from Powerhouses- Launch pad damaged as Russian rocket blasts off for space station, agency says
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- Vote in favor of your Number one kind of juice
- 'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- Blood pressure drug recalled for possible cross-contamination
- 4 Home Rec center Hardware Decisions for Little Spaces
- Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
